Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation

S Sean Tu; Sarosh Nagar; Aaron S Kesselheim; Zhigang Lu; Benjamin N Rome

doi:10.1001/jama.2023.3079

Five-Year Sales for Newly Marketed Prescription Drugs With and Without Initial Orphan Drug Act Designation

JAMA. 2023 May 9;329(18):1607-1608. doi: 10.1001/jama.2023.3079.

Authors

S Sean Tu¹, Sarosh Nagar², Aaron S Kesselheim², Zhigang Lu², Benjamin N Rome²

Affiliations

¹ West Virginia University College of Law, Morgantown.
² Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, Massachusetts.

No abstract available

Plain language summary

This study evaluates sales revenue earned in the first 5 years for newly marketed brand-name drugs with and without an initial orphan drug designation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Commerce* / economics
Commerce* / legislation & jurisprudence
Commerce* / statistics & numerical data
Commerce* / trends
Legislation, Drug / economics
Legislation, Drug / statistics & numerical data
Marketing / economics
Marketing / legislation & jurisprudence
Marketing / statistics & numerical data
Orphan Drug Production* / economics
Orphan Drug Production* / legislation & jurisprudence
Orphan Drug Production* / statistics & numerical data
Prescription Drugs* / economics
United States / epidemiology

Substances

Prescription Drugs